All In Biotech

Drug Trial Radar · NCT07469228

A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study, Comparing Tretinoin Gel Microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (Tretinoin) Gel Microsphere, 0.04% (Reference Listed Drug) in the Treatment of Acne Vulgaris.

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,043 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,043

Actual

Start

Aug 4, 2025

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Tretinoin Gel Microsphere, 0.04%Drug

    The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.

  • RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%Drug

    The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.

  • Placebo ControlDrug

    The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate & evaluate the therapeutic, equivalence and safety of the investigational productTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Pharmaceutical Industries, Inc.

    Hawthorne, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.